Since the mutation status of BRAF has been used as a prognosis biomarker, and the prognosis of WT Bf-CM seems relatively poor owing to the lack of therapeutic options [1–3, 39], this study aimed to construct a predictive signature for the prognosis of WT Bf-CM patients. The gene discussed is BRAF; the disease is cutaneous mastocytosis.